Quick Takeaways
- TANG CAPITAL MANAGEMENT LLC filed SCHEDULE 13G for Keros Therapeutics, Inc. Common Stock, par value $0.0001 per share (KROS).
- Disclosed ownership: 7.9%.
- Date of event: 15 Oct 2025.
Quoteable Key Fact
"TANG CAPITAL MANAGEMENT LLC disclosed 7.9% ownership in Keros Therapeutics, Inc. Common Stock, par value $0.0001 per share (KROS) on 15 Oct 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT, LLC | 7.9% | 2,418,984 | 0 | 2,418,984 | Kevin Tang | Manager | |
| KEVIN TANG | 7.9% | 2,418,984 | 0 | 2,418,984 | Kevin Tang | Self | |
| TANG CAPITAL PARTNERS, LP | 5.2% | 1,579,237 | 0 | 1,579,237 | Kevin Tang | Manager, Tang Capital Management, LLC, General Partner | |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP | 2.7% | 839,747 | 0 | 839,747 | Kevin Tang | Manager, Tang Capital Management, LLC, General Partner | |
| TANG CAPITAL PARTNERS III, INC | 0% | 0 | 0 | 0 | Kevin Tang | Chief Executive Officer | |
| TANG CAPITAL PARTNERS IV, INC | 0% | 0 | 0 | 0 | Kevin Tang | Chief Executive Officer |